Introduction: The Intersection of Obesity and Hypertension
The global prevalence of obesity and hypertension continues to rise in tandem, creating a synergistic risk for cardiovascular disease, stroke, and chronic kidney disease. While lifestyle modifications remain the cornerstone of management, the physiological drivers of obesity-related hypertension—including sympathetic nervous system overactivation, renin-angiotensin-aldosterone system (RAAS) dysregulation, and physical compression of the kidneys—often necessitate pharmacological intervention. The advent of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized obesity treatment, but the search for even more potent combinations that address metabolic and hemodynamic parameters simultaneously is ongoing. The REDEFINE 1 trial, evaluating the fixed-dose combination of semaglutide and cagrilintide (CagriSema), represents a pivotal step in this evolution. This analysis specifically looks at how this combination therapy impacts blood pressure, a critical metric for long-term cardiovascular outcomes.
